SCHEMBL7147671

SCHEMBL7147671

CCOc1c(F)ccc(Br)c1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
LMNA P02545 3/20 0.37
ALDH1A1 P00352 2/20 0.37
GAA P10253 1/20 0.37
NQO1 P15559 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
TUBB1 Q9H4B7 1/20 0.34
HTT P42858 3/20 0.33
MAPT P10636 3/20 0.33
NPSR1 Q6W5P4 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
HPGD P15428 1/20 0.32
ALPG P10696 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
ALOX5AP P20292 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31015943 1.00 THRB (0.37) THRBSMN1; SMN2LMNAALDH1A1GAA
SCHEMBL24707510 0.86 SMN1; SMN2 (0.36) THRBSMN1; SMN2LMNAALDH1A1GAA
SCHEMBL22114350 0.85 NQO1 (0.40) ALDH1A1NQO1L3MBTL1TUBB1HTT
SCHEMBL2123778 0.82 TUBB1 (0.40) THRBSMN1; SMN2LMNAALDH1A1GAA
SCHEMBL1223417 0.80 THRB (0.39) THRBSMN1; SMN2LMNAALDH1A1GAA
SCHEMBL28358531 0.80 ALOX5AP (0.33) ALOX5APFEN1
SCHEMBL22701125 0.79 NQO1 (0.36) SMN1; SMN2ALDH1A1GAANQO1L3MBTL1
SCHEMBL21823585 0.79 TUBB1 (0.44) SMN1; SMN2LMNAALDH1A1GAAL3MBTL1
SCHEMBL31096258 0.79 TUBB1 (0.44) SMN1; SMN2LMNAALDH1A1GAAL3MBTL1
SCHEMBL4024514 0.78 MEP1B (0.44) SMN1; SMN2ALDH1A1TUBB1ALOX5APFEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12466803-B2 BCKDK inhibitors and/or degraders PFIZER INC. (US) 2025-11-11 US disclosed
WO-2023100061-A1 3-PHENYL-1-BENZOTHIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS BRANCHED-CHAIN ALPHA KETO ACID DEHYDROGENASE KINASE INHIBITORS FOR THE TREATMENT OF DIABETES, KIDNEY DISEASES, NASH AND HEART FAILURE PFIZER INC. (US) 2023-06-08 WO disclosed
US-20230167080-A1 BCKDK INHIBITORS AND/OR DEGRADERS PFIZER INC. (US) 2023-06-01 US disclosed
WO-2003095441-A1 INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME PFIZER INC. (US) 2003-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12466803-B2 BCKDK inhibitors and/or degraders BCKDK, KHK, PDK4 THRB 1838/4885SMN1; SMN2 3687/4885LMNA 2031/4885
US-20230167080-A1 BCKDK INHIBITORS AND/OR DEGRADERS BCKDK, KHK, PDK4 THRB 1838/4885SMN1; SMN2 3687/4885LMNA 2031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.